Viberzi® (eluxadoline) - Prior Authorization/Medical Necessity - UnitedHealthcare Commercial Plansopen_in_new
Prior authorization and medical necessity criteria for Viberzi (eluxadoline) for treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults under UnitedHealthcare commercial plans; includes initial and reauthorization criteria, authorization duration, and notes about automated approvals and supply limits.
Effective Date set to 7/1/2025 and program listed as Prior Authorization/Medical Necessity for Viberzi.
Initial authorization criteria require IBS-D diagnosis and failure/contraindication/intolerance to a tricyclic antidepressant.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.